8-K: Forte Biosciences Acquired by argenx for $2.2 Billion

Sentiment:

Current Report (Form 8-K) Completion of Acquisition 27 August 2026 4:15 PM

Forte Biosciences, Inc. announced the successful completion of its acquisition by argenx BV, with shareholders receiving $77.00 per share in cash.

Summary

Forte Biosciences, Inc. has been acquired by argenx BV through a tender offer and subsequent merger.
The tender offer, which commenced on August 6, 2026, successfully acquired approximately 87.13% of Forte Biosciences' outstanding shares.
The acquisition was completed on August 27, 2026, with Forte Biosciences becoming a wholly owned subsidiary of argenx.
Shareholders who tendered their shares received $77.00 per share in cash.
Options, RSUs, and pre-funded warrants were also cashed out based on the $77.00 per share offer price.
The total funds used by argenx for the transaction amounted to approximately $2.2 billion, funded by argenx's cash on hand.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, marking the successful completion of a significant acquisition at a premium price, which is generally favorable for existing shareholders.

Positives

Successful completion of the acquisition by argenx.
Shareholders received a premium price of $77.00 per share in cash.
The transaction was funded entirely by argenx's existing cash reserves, indicating financial strength.
The merger was completed efficiently under Delaware General Corporation Law Section 251(h), without requiring a stockholder vote.

Negatives

Forte Biosciences is no longer a publicly traded entity, meaning shareholders no longer have direct ownership in a listed company.
All outstanding stock options and RSUs were cancelled, with holders receiving cash payments, which may be viewed negatively by those who preferred continued equity participation.

Risks

The filing does not explicitly mention any ongoing risks related to the acquisition itself, as it has been completed.
The delisting from NASDAQ and termination of reporting obligations means less public information will be available going forward.

Future Outlook

As Forte Biosciences is now a wholly owned subsidiary of argenx, its future outlook is integrated into argenx's strategic plans. Specific forward-looking statements for Forte Biosciences as an independent entity are no longer applicable.

Management Comments

The filing incorporates by reference previous disclosures regarding the Merger Agreement and Transactions.
The company notified NASDAQ of the merger completion and requested suspension of trading and delisting.

Industry Context

StockSavvy.ai notes that this acquisition aligns with the trend of larger biotechnology firms acquiring smaller, innovative companies to expand their pipelines and market presence. argenx's acquisition of Forte Biosciences likely aims to integrate Forte's technology or product candidates into argenx's existing portfolio, particularly in the immunology space.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Director	Paul A. Wagner, Ph.D., Steven Kornfeld, Scott Brun, M.D., Barbara K. Finck, M.D., Stephen K. Doberstein, Ph.D., Richard Vincent, Shiv Kapoor, David Gryska	Arjen Lemmen, Karl Gubitz, Hemamalini (Malini) Moorthy	August 27, 2026	Cessation of previous directors and appointment of Purchaser's directors following the merger.
Officer	All officers of Forte Biosciences	Arjen Lemmen, Karl Gubitz, Hemamalini (Malini) Moorthy	August 27, 2026	Cessation of previous officers and appointment of Purchaser's officers following the merger.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Amendments to Certificate of Incorporation and Bylaws	The Company's certificate of incorporation and bylaws were amended and restated in their entirety as part of the merger.	August 27, 2026	These amendments reflect the change in ownership and corporate structure, aligning with the new parent company's governance framework. The amended certificate of incorporation limits director liability and allows for broad indemnification. The amended bylaws detail corporate governance procedures for stockholders and directors.

Legal Proceedings

No new legal proceedings are mentioned in this filing.

Related Party Transactions

No related party transactions are detailed in this filing.

Stakeholder Impact

Shareholders: Received $77.00 per share in cash, realizing their investment.
Option and RSU Holders: Received cash payments for their awards.
Employees: May experience changes in roles, responsibilities, and reporting structures as part of the integration into argenx.
Creditors: The acquisition was funded by cash, suggesting no immediate impact on existing debt obligations, but future integration may affect financial arrangements.

Next Steps

Delisting of Forte Biosciences' common stock from the NASDAQ Stock Market.
Termination of Forte Biosciences' reporting obligations under the Exchange Act.
Integration of Forte Biosciences into argenx's operations.

Key Dates

Date	Description
July 26, 2026	Date of the Agreement and Plan of Merger.
August 6, 2026	Purchaser commenced the tender offer.
August 26, 2026	Expiration Date of the tender offer.
August 27, 2026	Effective Date of the Merger and filing of this Form 8-K.

Recommendation

hold

The acquisition has been completed at a premium, providing a clear exit for existing shareholders. For new investors, the company is now private and part of a larger entity, making a direct investment recommendation difficult without further insight into argenx's strategic integration plans and future performance of the combined entity.

Keywords

acquisition, merger, tender offer, argenx, Forte Biosciences, delisting, cash out, Nasdaq

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.